GHRS News and Press, GH Research PLC From 08/23/23

2023-08-23 15:24:11 ET GH Research press release ( NASDAQ: GHRS ): Q2 Non-GAAP EPS of -$0.15. Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023. For further details see: GH Research Non-GAAP EPS of -$...

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided...

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

2023-06-29 12:54:19 ET President Joe Biden is very "open-minded about" psychedelic medications, his youngest brother Frank Biden said during an interview on Wednesday, recalling a conversation the siblings had about the psychoactive substances. "He is very open-minded," the younger Bide...

2023-06-23 13:32:08 ET The U.S. Food and Drug Administration (FDA) published a new draft guidance on investigations into psychedelic drugs on Friday, detailing considerations for their clinical trials for the first time. The recommendations come at a time when there is growing public in...

2023-06-16 11:06:16 ET Summary GH Research PLC is developing mebufotenin, developed from toad venom, as an antidepressant. They have some early positive data. However, toad venom is a controlled substance and will face approval difficulties. GH Research PLC ( G...

2023-05-11 11:44:03 ET GH Research press release ( NASDAQ: GHRS ): Q1 GAAP EPS of -$0.21. Cash, cash equivalents, other financial assets and marketable securities were $246.1 million as of March 31, 2023, compared to cash, cash equivalents and marketable securities of $251...

DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided ...

2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...

2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...